Phill Craig

Phill Craig has a diverse professional background spanning various roles in the biotechnology and pharmaceutical industries. In 2017, they founded Start the Reaction, a company focused on innovation and entrepreneurship. Phill then served as the Leader of Tomorrow at the GapSummit 2019, a biotechnology leadership summit organized by Global Biotech Revolution. From 2019 to 2020, Phill worked as a Software Developer at SaasDo, developing SaaS products. Phill also worked at Raveback as the Head of Product, where they sourced customer insights to inform product development. In 2021, Phill had a research placement at Cambridge Healthcare Research, conducting industry research on autoimmunity biomarkers. Phill then transitioned to consulting, working as a Life Science & Healthcare Consultant at DST Consulting, specializing in strategic consulting for the healthcare and life sciences industries. In 2022, Phill held Business Analyst roles at Molecule 2 Medicine, Grey Wolf Therapeutics, Pathios Therapeutics, and ThirtyFiveBio, where they provided valuable analysis and support in the biotech and pharmaceutical sectors.

Phil Craig completed their education in a chronological order. Phill attended John McGlashan College from 2001 to 2007 and pursued the International Baccalaureate program. From 2008 to 2013, they enrolled at the University of Otago, where they earned a Bachelor of Science (B.Sc.) in Chemistry and a Bachelor of Commerce (B.Com.) in International Business. In 2010 to 2011, Phil studied abroad at Université Jean Moulin (Lyon III), completing a Bachelor of Commerce (B.Com.) with a field of study in International Business. Finally, from 2020 to 2021, they attended the University of Cambridge and obtained a Master of Philosophy (MPhil) in Bioscience Enterprise.